Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03656510 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
NCT03656510 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 246 participants.
The verdict
NCT03656510, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetic/pharmacodynamic relationships of different oral dose levels of JNJ-53718678 in children greater than or equal to 28 days and less than or equal to 3 years of age with respiratory syncytial virus (RSV) disease (hospitalized participants \[Cohort 1\] or outpatients \[Cohort 2\]).
Interventions
- DRUG Placebo
- DRUG JNJ-53718678
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2022-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03656510
The ClinicalTrials.gov registry entry for NCT03656510 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03656510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03656510 about?
NCT03656510 is a clinical study titled "Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection". The purpose of this study is to evaluate the antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetic/pharmacodynamic relationships of different oral dose levels of JNJ-53718678 in children greater than or equal to 28 days and less than or equal to 3 years of age with respira...
What is the current status of trial NCT03656510?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2018-11-29. Estimated completion is 2022-04-18.
What interventions are being tested in trial NCT03656510?
The interventions under investigation include: Placebo (DRUG), JNJ-53718678 (DRUG).
Who is sponsoring clinical trial NCT03656510?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.